Significant events until 8 February 2020

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.

2019

Grifols presents its latest Alzheimer's clinical trial data December 6, 2019
Payment details of the interim dividend on account of 2019 earnings November 20, 2019
Grifols completes its debt-refinancing in record time and with strong acceptance for EUR 5,800 million November 15, 2019
Grifols and Shanghai RAAS obtain authorization for their strategic alliance in China November 13, 2019
Grifols approves the payment of an interim dividend on account of 2019 October 31, 2019
Grifols increases its revenues by 14.5% to EUR 3,738 million October 29, 2019
Grifols to initiate secured debt-refinancing for an amount of EUR 5,300 million October 28, 2019
Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan July 31, 2019
Grifols presents additional encouraging Alzheimer's trial results July 16, 2019
Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies July 4, 2019
Information on the resolutions approved at the General Meeting of Shareholders on May 24, 2019 May 24, 2019
Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance May 7, 2019
Grifols expands its plasma collection network by acquiring IBBI May 2, 2019
Notice of Annual General Shareholders' Meeting 2019 April 16, 2019
Grifols presents additional results of its AMBAR clinical trial to treat Alzheimer´s March 29, 2019
Grifols enters a strategic alliance with Shanghai RAAS in China March 7, 2019

2018

Grifols monetizes its recent strategic acquisitions and reinforces its financial structure to support growth opportunities December 31, 2018
Change of category of Mr. Ramón Riera Roca December 18, 2018
Payment details of the interim dividend on account of 2018 earnings November 23, 2018
Grifols enters talks with Shanghai RAAS regarding a possible investment November 21, 2018
Grifols approves the payment of an interim dividend on account of 2018 November 2, 2018
Grifols presents AMBAR top-line results at the "Clinical Trials on Alzheimer's Disease" (CTAD) October 27, 2018
Response to recent published research October 3, 2018
Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives September 7, 2018
Grifols expands its plasma collection network by acquiring 24 Biotest centers in the United States August 1, 2018
Grifols closes the acquisition of Haema AG June 4, 2018
Information on the resolutions approved at the Annual General Meeting of Shareholders on May 25, 2018 May 25, 2018
Grifols reaches an agreement with Boya Bio-Pharmaceutical to open plasma collection centers in China May 10, 2018
Notice of Annual General Shareholders' Meeting 2018 April 20, 2018
Grifols has entered into an agreement with Aton GmbH for the purchase of 100% of the shares of German based pharmaceutical company Haema AG March 20, 2018
Appointment of new Chairperson of the Audit Committee February 23, 2018
Impact of the U.S. tax reform and other non-recurring items – Additional information (Spanish version) January 31, 2018
Impact of the U.S. tax reform and other non-recurring items – Additional information (Spanish version) January 31, 2018
Impact of the U.S. tax reform and other non-recurring items – Additional information January 30, 2018
Impact of the U.S. tax reform and other non-recurring items January 30, 2018
Grifols acquires a 51% in the U.S. technology firm MedKeeper for USD 98 million January 26, 2018

2017

Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives December 5, 2017
Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components November 22, 2017
FDA approval of genetic test for alpha-1 deficiency and EMA approval of fibrin sealant November 17, 2017
Payment details of the interim dividend on account of 2017 earnings November 16, 2017
FDA approves a new Grifols product, fibrin sealant ("Fibrin Sealant") November 6, 2017
The Board of Directors approves an interim dividend on account of 2017 results October 30, 2017
FDA approves Grifols Prolastin®-C Liquid for the treatment of alpha-1 antitrypsin deficiency September 22, 2017
Grifols announces the acquisition of an additional 40% equity stake in Kiro Grifols July 25, 2017
Grifols acquires a 44% shareholding in GigaGen July 5, 2017
Manufacturing and supply agreement June 7, 2017
Information on the resolutions approved at the Annual General Meeting of Shareholders on May 26, 2017 May 26, 2017
Listing on the ISE of the Senior Unsecured Notes due 2025 and delisting of the Notes due 2022 May 2, 2017
Notice of Annual General Shareholders' Meeting 2017 April 21, 2017
Grifols has closed EUR 1.0 billion senior unsecured bond issue concluding its debt refinance process April 18, 2017
Communication to the Irish Stock Exchange April 6, 2017
Communication to the Irish Stock Exchange March 20, 2017
Grifols has concluded the refinancing process of part of its financial debt February 6, 2017
Grifols closes the acquisition of Hologic's share of NAT donor screening unit January 31, 2017
Grifols to acquire the 49% in Access Biologicals January 12, 2017
Grifols starts the refinancing process January 10, 2017

2016

Information regarding the decisions taken by the Board of Directors in accordance with the Succession Plan approved on 10 December 2015 December 19, 2016
Grifols agreed to acquire Hologic's share of NAT donor screening unit for USD 1,850 million December 14, 2016
Details of the interim dividend payment on account of 2016 earnings November 21, 2016
The Board of Directors approves the payment of an interim dividend and a new internal code of conduct October 31, 2016
The United States Department of Justice closes its inquiry into Grifols October 7, 2016
Information on the resolutions approved at the Annual General Meeting of Shareholders on May 27, 2016 May 27, 2016
Grifols signed an agreement with Singulex, Inc. to acquire a 20%. This agreement includes a worldwide exclusive licence for the use of its technology May 17, 2016
Grifols informs that the transaction to acquire a 49% stake in IBBI closed under the terms and conditions previously indicated May 12, 2016
Notice of Annual General Shareholders' Meeting 2016 April 22, 2016
Agreements signed to acquire a 49% stake in IBBI April 8, 2016
Industrial investments plan 2016-2021 for the Bioscience division March 8, 2016
Grifols notifies the acquisition of 32.93% of the share capital of Progenika Biopharma, S.A. increasing its stake to 89.08% March 3, 2016

2015

Grifols informs that the newly-issued shares resulting from the stock split will begin trading on January 4, 2016 December 30, 2015
The Board of Directors approves the Succession Plan of Grifols December 14, 2015
Grifols announces a stock split of the company's shares December 3, 2015
Details of payment of interim dividend on account of 2015 profit November 30, 2015
Certification of compliance with the obligations of certain provisions of the Companies Act (Spanish version) November 26, 2015
Grifols agrees long term loan with the European Investment Bank October 28, 2015
Payment of interim dividend on account of 2015 profit October 26, 2015
Grifols has signed, jointly with Ortho Clinical Diagnostics, a restated and extended contract through 2026 with Abbott for the production of antigens July 20, 2015
Information on the resolutions approved at the Annual General Meeting of Shareholders on May 29, 2015 May 29, 2015
Notice of Annual General Shareholders' Meeting 2015 April 24, 2015
Grifols informs about the definitve agreement whereby will make a major equity investment in Alkahest March 4, 2015
Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles December 31, 2014
Payment of interim dividend on account of 2014 profit November 26, 2014
Grifols receives FDA approval for its new fractionation plant in Clayton November 17, 2014
The board of directors approves the payment of an interim dividend on account of 2014 earnings October 21, 2014
Grifols subscribes to a capital increase of the company Kiro Robotics, S.L. September 19, 2014
Information on the resolutions approved at the Annual General Meeting of Shareholders on May 30, 2014 May 30, 2014
Senior Unsecured notes admitted to listing in the Irish Stock Exchange May 29, 2014
Notice of Annual General Shareholders' Meeting 2014 April 25, 2014
Grifols opens new plasma fractionation plant in Spain (Press release) April 4, 2014
The Japanese Red Cross signs a seven-year agreement to use Grifols' Procleix Nucleic acid blood screening systems March 31, 2014
Grifols has concluded the refinancing process of its debt March 17, 2014
Grifols issues $1billion senior unsecured notes March 6, 2014
Grifols starts the refinancing process February 24, 2014
Appointment of new president of the Audit Committee February 24, 2014
Grifols closes the acquisition of Novartis AG diagnostic business unit January 10, 2014
Grifols signs a US$1.5billion bridge loan that will be used to acquire the diagnostic business unit of Novartis AG January 3, 2014
Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 17, 2013 December 17, 2013
Grifols communicates the acquisition of 21.30% of the biotechnological company TiGenix N.V. November 20, 2013
Notice of Extraordinary General Shareholders' Meeting December 2013 November 15, 2013
Grifols to acquire Novartis diagnostics business unit for US$1,675 million November 11, 2013
Grifols, S.A. informs the start of a clinical trial in phase I of the ABvac40 vaccine for patients with Alzheimer's disease September 18, 2013
Grifols informs of the closing of the subscription of the shares of Aradigm Corp August 28, 2013
Grifols informs that Moody's Investors Services has upgraded the company credit ratings July 15, 2013
Information on the resolutions approved at the Annual General Shareholders Meeting on May 24, 2013 May 24, 2013
Grifols signs an exclusive worldwide license agreement with Aradigm to develop and commercialize Pulmaquin™ May 21, 2013
Notice of Annual General Shareholders' Meeting 2013 April 22, 2013
New non-voting class B shares admitted to listing April 19, 2013
Registration with the Commercial Registry of the share capital increase and the issuance of new Class B non-voting shares April 16, 2013
Grifols purchases ADRs from Cerberus' March 12, 2013
Grifols announces the acquisition of 60% of the share capital of Progenika Biopharma S.A. March 4, 2013
New non-voting class B shares admitted to listing January 11, 2013
Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares January 4, 2013
Announcement of Grifols S.A Share Capital Increase December 10, 2012
Information on the proposals adopted by the Extraordinary General Shareholders Meeting on December 4, 2012 December 4, 2012
The US Department of Justice (DOJ) notified of the official declination to all inquiries that were underway since July 2009 in Talecris November 30, 2012
Notice of Extraordinary General Shareholders' Meeting December 2012 October 29, 2012
CNMV Communications September 19, 2012
Standar & Poor´s: Rating upgrade August 1, 2012
ADS's Exchange Ratio Modification July 23, 2012
Grifols informs that Moody's Investors Services has upgraded its ratings July 9, 2012
Information on the resolutions approved at the Annual General Shareholders Meeting on May 24, 2012 May 24, 2012
Notice of General Shareholders' Meeting 2012 April 20, 2012
Grifols, S.A. announces that it has acquired 51% of the share capital of Araclon Biotech, S.L. March 15, 2012
Grifols informs that has successfully closed the negotiations to amend and improve the terms and conditions of the Credit Agreement February 14, 2012
CNMV Communication January 18, 2012
New non-voting class B shares admitted to listing in Spain December 29, 2011
Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares December 22, 2011
Announcement of Grifols S.A Share Capital Increase December 5, 2011
Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 2, 2011 December 2, 2011
3Q results reporting date postponed November 8, 2011
Notice of Extraordinary General Shareholders' Meeting December 2011 October 28, 2011
Grifols announces the closing of the transaction to acquire 100% of the capital of the Australian-Swiss group, Lateral-Medion August 2, 2011
Execution of the agreement with Kedrion June 3, 2011
Closing of the acquisition of Talecris Biotherapeutics June 2, 2011
Grifols and Talecris announce that the FTC accepted for public comment the Consent Agreement June 1, 2011
Changes in the board of directors June 1, 2011
Registration of the "Nota sobre Acciones" (Securities Note) of the Class B non voting shares with the "CNMV" (National Securities Market Commission) June 1, 2011
Information on the resolutions approved at the Ordinary general shareholders meeting May 24, 2011
Grifols and Talecris Biotherapeutics announce the signing of a Consent Agreement with FTC Staff May 2, 2011
Notice of Annual General Shareholders Meeting 2011 April 19, 2011
Grifols and Talecris disclose the extension of the outside date under their merger agreement and the financing commitments March 4, 2011
New timing agreement with the FTC to provide advance notice of the consummation of the acquisition of Talecris February 11, 2011
Agreement with the FTC to extend the timing of the resolution for the acquisition of Talecris February 4, 2011
Information of the resolutions passed at the Extraordinary General Shareholders Meeting held January 25th 2011 January 25, 2011
Filing with the Securities Exchange Commission of the F-4 relating to the proposed acquisition of Talecris January 17, 2011
Grifols closes USD 1.1 billion bond issue (This release will not be distributed in the United States of America, Canada, Australia or Japan) January 13, 2011
Notice of Extraordinary General Meeting December 20, 2010
Grifols obtains EMA license to market its IVIG, Flebogamma® DIF, at 10% concentration December 15, 2010
Grifols signs term loan agreements related to Talecris acquisition for USD 3.4 billion November 24, 2010
Changes in the merger consideration of the Agreement and Plan of Merger as a consequence of the settlement of a class action November 11, 2010
Resolution by the " Comisión Nacional de la Competencia" November 4, 2010
Clarification on press releases published in certain media November 2, 2010
Shareholders' commitment to the proposed acquisition of Talecris September 30, 2010
Grifols expects to close for an amount of USD1.5B the first tranche of the syndicated Financing to acquire Talecris September 15, 2010
Grifols obtains FDA license in the US market for its IVIG Flebogamma® DIF 10% concentration September 2, 2010
Preliminary version of the F4 filed with the SEC in connection with the proposed acquisition of Talecris August 10, 2010
Grifols obtains its first crédit rating from Standard & Poor's and Moody's July 20, 2010
Final dividend 2009 June 23, 2010
Information on the resolutions passed at the Annual General Shareholders Meeting on June 21st June 21, 2010
Voting agreement - amendment June 10, 2010
Agreement and Plan of Merger among Grifols and Talecris Biotherapeutics Holdings Corp June 10, 2010
Acquisition Announcement of Talecris Biotherapeutics Holdings Corp June 7, 2010
Voting agreement June 7, 2010
Analyst and investors' presentation regarding acquisition of Talecris Biotherapeutics Holdings Corp June 7, 2010
Conference call details June 7, 2010
Notice of Annual General Meeting May 18, 2010
Resignation of Christian Purlow from the Board of Directors January 12, 2010
Grifols and financial institutions unanimously agree the novation of the syndicated facility December 16, 2009
Interim Dividend 2009 - Clarification December 14, 2009
Interim Dividend 2009 December 14, 2009
Change of registered address November 3, 2009
Grifols completes its USD600 million corporate bond issue in the US October 7, 2009
Grifols announces corporate debt issuance in USA September 29, 2009
The shares of Grifols will be traded in the United States through ADRs May 28, 2009
Announcement on Grifols dividend payment May 20, 2009
Information on the resolutions passed by the General Shareholders' Meeting held on May 15th, 2009 May 15, 2009
Annual General Meeting Announcement April 7, 2009
Grifols signs two supply agreements in brazil March 31, 2009
Grifols acquires control over a Swiss and Australian group through a €25 million investment March 3, 2009
D. Anna Veiga joins the Board of Directors of Grifols as independent director (Spanish Version) December 10, 2008
Flebogamma® DIF receives marketing license in Australia (Spanish Version) October 14, 2008
The Company submits agreements approved in the Annual General Meeting on June 13, 2008 (Spanish Version) June 13, 2008
The Company announces a dividend payment for June 23, 2008 (Spanish Version) June 13, 2008
Grifols obtains a syndicated loan totaling 350 million euros (Spanish Version) May 26, 2008
Annual General Meeting Announcement Addendum (Spanish Version) May 22, 2008
Annual General Meeting Announcement (Spanish Version) May 7, 2008
The Company notifies the resignation of Mr. Thomas E. Doster from his positions as member of the Board of Directors and the Appointments and Remunerations Committee (Spanish Version) April 29, 2008
Grifols signs agreement with Stough Development Corporation to open 10 new plasma collection Centers in the United States (Spanish Version) March 12, 2008
Grifols closed without agreement the due diligence process started with the Italian company Diesse (Spanish Version) February 23, 2008
Appointment of Edgar D. Jannotta as member of the Appointments and Remuneration Committee (Spanish Version) December 27, 2006
Grifols to announce Capital Investment Plan for 400 million euro over the next five years October 29, 2007
EMEA authorization to distribute Flebogamma DIF® in Europe (Spanish Version) August 27, 2007
Announcement of transfer of shares (Spanish Version) August 10, 2007
Announcement on Grifols dividend payment (Spanish Version) June 26, 2007
Information on the resolutions passed by the General Shareholders Meeting held on June 20th, 2007 (Spanish Version) June 21, 2007
Annual General Meeting Announcement (Spanish Version) May 14, 2007
Grifols enters into an agreement for the management of four new plasma centers in the USA (Spanish Version) May 4, 2007
Grifols has entered into an agreement for the acquisition of Diesse. The closing of the transaction is subject to the outcome of the due diligence review, which the company expects will last until next June. (Spanish Version) April 18, 2007
Morgan Stanley & Co. International Ltd announces the completion of the placement (Spanish Version) April 10, 2007
Morgan Stanley & Co. International Ltd announces a private placement of 1.41% of Grifols S.A. share capital (accelerated bookbuilding) (Spanish Version) April 10, 2007
Extension of the Communication number 22.629 on the FDA approval for the indication of von Willebrand disease. (Spanish Version) February 2, 2007
The FDA approves the indication of von Willebrand disease for Alphanate (Spanish Version) February 1, 2007
Grifols licensed by the FDA to market a new generation of IGIV in the United States (Spanish version) December 27, 2006
Appointment of new Director through co-option procedure (Spanish version) December 20, 2006
Amendment to the syndicated loan (Spanish version) November 21, 2006
Changes in the Board of Directors and other governing bodies of the Company (Spanish version) July 19, 2006
Public Offering to subscribed Grifols S.A. shares – additional information ( Spanish version) June 19, 2006
Information regarding the execution of the green shoe option over 7,000,000 shares of Grifols (Spanish version) May 22, 2006
Additional information to the information brochure of the public subscription offer for shares in GRIFOLS, S.A. (Spanish version) May 16, 2006
Additional information to the information brochure of the public subscription offer for shares in GRIFOLS, S.A. (Spanish version) May 15, 2006